Related Experiment Videos
Biomaterial-Based Strategies for Gout Therapy: Recent Advances, Current Challenges, and Future Perspectives - A
Zhicheng Zhang1, Ruiyan Li1, Xiaohan Wu2
1Orthopedic Medical Center, The Second Hospital of Jilin University, Changchun, 130022, People's Republic of China.
International Journal of Nanomedicine
|July 8, 2026
Summary
Biomaterials offer advanced gout treatment by improving drug delivery and reducing side effects. This review categorizes recent biomaterial applications, highlighting their potential and challenges for effective gout management.
Area of Science:
- Biomaterials Science
- Rheumatology
- Drug Delivery Systems
Background:
- Gout is an inflammatory disease caused by monosodium urate (MSU) crystal deposition.
- Biomaterials show potential for enhanced gout treatment due to biocompatibility and targeted delivery.
- Current gout therapies face challenges in solubility, bioavailability, and systemic side effects.
Purpose of the Study:
- To systematically review biomaterial applications in gout therapy over the last five years.
- To categorize and analyze nano-drug delivery, microneedle systems, and novel biomaterials for gout.
- To summarize therapeutic roles, advantages, and limitations of biomaterial platforms in gout management.
Main Methods:
- Systematic review of biomaterial applications in gout treatment (past 5 years).
- Categorization of biomaterials including nano-drug delivery and microneedle systems.
- Analysis of design principles, mechanisms, and therapeutic roles of different biomaterial platforms.
Main Results:
- Nano-drug delivery systems and microneedle systems enhance drug solubility and bioavailability for gout.
- Biomaterials enable targeted and stage-specific therapeutic interventions, reducing systemic adverse effects.
- Review identifies potential therapeutic roles, advantages, and limitations of various biomaterial strategies.
Conclusions:
- Biomaterial-based strategies offer promising, targeted approaches for gout therapy.
- Further research and preclinical evaluation using relevant animal models are needed.
- Overcoming translational challenges is key to developing clinically relevant biomaterial therapies for gout.
Related Concept Videos
01:19Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...